Zhejiang Jolly Pharmaceutical Co.,LTD Stock

Equities

300181

CNE100001096

Pharmaceuticals

End-of-day quote Shenzhen S.E. 18:00:00 2024-07-17 EDT 5-day change 1st Jan Change
14.52 CNY +2.04% Intraday chart for Zhejiang Jolly Pharmaceutical Co.,LTD -6.62% +36.21%

Financials

Sales 2024 * 2.63B 362M 496M Sales 2025 * 3.23B 445M 610M Capitalization 10.18B 1.4B 1.92B
Net income 2024 * 547M 75.26M 103M Net income 2025 * 664M 91.36M 125M EV / Sales 2024 * 3.87 x
Net cash position 2024 * - 0 0 Net cash position 2025 * - 0 0 EV / Sales 2025 * 3.15 x
P/E ratio 2024 *
18.6 x
P/E ratio 2025 *
15.3 x
Employees 2,687
Yield 2024 *
4.34%
Yield 2025 *
5.3%
Free-Float 72.13%
More Fundamentals * Estimated data
Dynamic Chart
Zhejiang Jolly Pharmaceutical Co.,LTD Announces Director Changes CI
Zhejiang Jolly Pharmaceutical Co.,LTD announced that it has received CNY 909.999997 million in funding CI
Zhejiang Jolly Pharmaceutical Co.,LTD Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Zhejiang Jolly Pharmaceutical Co.,LTD Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Zhejiang Jolly Pharmaceutical Co.,LTD(XSEC:300181) added to S&P Global BMI Index CI
Zhejiang Jolly Pharmaceutical Co.,LTD Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Zhejiang Jolly Pharmaceutical Co.,LTD Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Zhejiang Jolly Pharmaceutical Co.,LTD Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Zhejiang Jolly Pharmaceutical Co.,LTD Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Zhejiang Jolly Pharmaceutical Co.,LTD signed an equity transfer agreement to acquire the remaining 48.99% stake in Zhejiang Jolly Baicao Chinese Medicine Decoction Pieces Co., Ltd. from Chen Huan and Chen Zhaorong for RMB 75 million. CI
Zhejiang Jolly Pharmaceutical Co.,LTD completed the acquisition of 8% stake in Zhejiang Top Medicine Co.,Ltd. from Yu Yin. CI
Zhejiang Jolly Pharmaceutical Co.,LTD Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Zhejiang Jolly Pharmaceutical Co.,LTD Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Zhejiang Jolly Pharmaceutical Co.,LTD announced that it expects to receive CNY 910 million in funding CI
Zhejiang Jolly Pharmaceutical Co.,LTD agreed to acquire 8% stake in Zhejiang Top Medicine Co.,Ltd. from Yu Yin for CNY 10.7 million. CI
More news
1 day+2.04%
1 week-6.62%
Current month-3.97%
1 month-8.56%
3 months+8.76%
6 months+35.07%
Current year+36.21%
More quotes
1 week
14.01
Extreme 14.01
14.96
1 month
13.92
Extreme 13.92
16.07
Current year
8.36
Extreme 8.36
17.28
1 year
8.36
Extreme 8.36
17.28
3 years
7.07
Extreme 7.07
17.28
5 years
4.64
Extreme 4.64
17.28
10 years
3.33
Extreme 3.33
18.18
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 18-01-15
Director/Board Member 49 21-01-24
Director/Board Member 44 17-12-31
Members of the board TitleAgeSince
Chairman 62 03-08-26
Director/Board Member 52 17-01-12
Director/Board Member 52 20-03-30
More insiders
Date Price Change Volume
24-07-18 14.52 +2.04% 15,691,250
24-07-17 14.23 -2.67% 14,508,960
24-07-16 14.62 -1.22% 14,975,100
24-07-15 14.8 -1.40% 17,396,440
24-07-12 15.01 -3.47% 24,741,890

End-of-day quote Shenzhen S.E., July 17, 2024

More quotes
Zhejiang Jolly Pharmaceutical Co., Ltd. is a China-based company principally engaged in research, development, manufacture and sales of medicinal fungi series products. The Company’s main business is mainly involved in pharmaceutical manufacturing, among which the activities are involved in manufacture and sale of active pharmaceutical ingredients, tablets, capsules, granules, Lyophilized powders and other products. The main products include Wuling series, bailing tablets series and Chinese medicine drinking tablets series, among others. Through its subsidiaries, the Company is also engaged in pharmaceutical circulation.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
14.52
Average target price
-
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 300181 Stock